following neurological procedures is essential to minimize postoperative complications. Despite these implications, limited clinical evidence exists regarding optimal BP management in neurocritical care patients. 3, 65 Low cerebral oxygenation, identified by partial pressure of PbtO 2 and jugular venous O 2 saturation monitoring, has been associated with a poor neurological outcome in patients with TBI and aneurysmal SAH. 7, 16, 30, 37, 62 Among the many acute physiological parameters used to predict cerebral oxygenation in the past, CPP and percentage of O 2 saturation had emerged as key determinants. Experience accrued in the past decade has shown that CPP, alveolar-arterial difference in PaO 2 , FiO 2 , and ICP individually affect cerebral oxygenation and that manipulation of each of these factors produces some benefit in improving cerebral O 2 delivery. 17, 30, [33] [34] [35] 51 Recent evidence suggests that PbtO 2 -directed clinical protocols improve O 2 delivery by manipulating the patient's physiology, are superior to ICP/CPP-directed protocols, and have been associated with an improved clinical outcome. 23, 26, 32, 55, 57, 60 Although the direct effects of antihypertensive agents on PbtO 2 have not been previously studied, nimodipine has shown to have a deleterious effect on PbtO 2 in patients with severe SAH and may contribute to poor outcome following stroke. 1, 3, 46, 56 Nicardipine, a dihydropyridine Ca channel blocker, acts as an arterial dilator thereby increasing blood flow to the brain and ameliorating cerebral vasospasm following aneurysmal SAH. It also has also been shown to have a positive effect on neuronal function in patients with ischemia. 18, 21, 24, 25 In this prospective, case-control study we investigated the role of intravenous nicardipine in the management of acute hypertensive emergencies associated with acute neurological disorders, and herein we report its effect on regional cerebral O 2 delivery.
Methods
Patients who required intravenous antihypertensive therapy between January 2004 and July 2005 and who met the following criteria were included in the study: age ≥ 16 years; a diagnosis of an acute neurological disorder such as TBI, aneurysmal SAH, or spontaneous or hypertensive ICH; and having been classified with 1 of the following hypertensive clinical syndromes 12 -ACVS, posttraumatic hypertension, 48 or acute postoperative hypertension. 22 The evaluation of all patients was performed prospectively. An institutional review board approved the study, and informed consent was obtained from patients' next of kin for the placement of a triple-lumen bolt for neuromonitoring, critical care management to optimize PbtO 2 , and for data collection. Patients with prior cardiovascular disease who were chronically treated with β blockers, preexisting hypertension requiring ≥ 2 antihypertensive agents, a known allergy or intolerance to Ca channel antagonists, renal or liver failure, or who had experienced previous undesirable side effects from intravenous nicardipine were excluded from the study.
Upon admission to the intensive care unit, resuscitation was aimed at the following physiological goals: PaO 2 > 100 mm Hg; PaCO 2 30-35 mm Hg; systolic BP > 120 mm Hg; central venous pressure 5-10 mm Hg; and urine output 0.5-1 ml/kg/hr. The bolt was inserted in a CT scan-evidenced "normal" area to measure ICP (Camino, Integra LifeSciences Corp), PbtO 2 , and brain temperature (Licox, Integra LifeSciences Corp).
1 Contused or infarcted brain was avoided to prevent erroneous readings. 53 Invasive multimodal continuous monitoring included placement of an arterial line for blood sampling, continuous MABP monitoring, and a central venous catheter for measurement of central venous pressure.
The surgical and or medical treatment of elevated ICP was performed using current neurosurgical guidelines (in brief, the removal of surgical mass lesion; use of cerebrospinal fluid drainage via ventriculostomy, mannitol and hyperventilation [range 30-35 mm Hg] for intracranial hypertension, sudden neurological deterioration, or signs of herniation and ICP > 20 mm Hg; maintenance of CPP > 60 mm Hg; and the use of barbiturate coma and decompressive craniectomy for refractory intracranial hypertension). A craniotomy was performed urgently to evacuate intracranial mass lesions when clinically indicated. Optimization of regional cerebral oxygenation was performed using a PbtO 2 -directed critical care-guided protocol as recently described. 38 Therefore, episodes of cerebral ischemia, defined as PbtO 2 < 20 mm Hg, were minimized via the use of normobaric hyperoxia and the manipulation of ventilator parameters, triple-H therapy, and hemoglobin manipulation. Patients with aneurysmal SAH underwent angiography and craniotomy for aneurysm clipping. Mannitol, sedatives, paralytics, thiopental sodium, and cerebrospinal fluid drainage via ventriculostomy were used to treat persistently elevated ICP, as clinically indicated.
Intravenous nicardipine was administered at an initial dose of 5 mg/hour and was gradually titrated (maximum dose 15 mg/hour) to achieve the following parameters: systolic BP < 160 mm Hg, diastolic BP < 90 mm Hg, MABP 90-110 mm Hg, and PbtO 2 > 20 mm Hg. Treatment was continued for as long as deemed clinically necessary by the attending physician. Drug infusion was suspended when the patient's BP was within the preset parameters but was restarted if the BP rose. These were counted as treatment episodes. Other antihypertensive agents were added as clinically indicated. Patients with persistent hypertension were treated with oral antihypertensive agents upon discharge from the hospital.
The primary end point of the study was an effective clinical reduction in BP. For the secondary end points we examined the effect of nicardipine on PbtO 2 . The changes in PbtO 2 and its relationship to the acute physiological parameters-such as systolic BP, diastolic BP, MABP, ICP, central venous pressure, FiO 2 , and CPP-were examined on admission, following PbtO 2 optimization, preinfusion, at 4 and 8 hours during infusion, and at each of the treatment episodes (using paired t-tests). 15, 39, 48, 64 The effect of the acute physiological parameters on PbtO 2 was explored using Spearman correlation coefficients, and mul tiple logistic regression analyses were performed to eval uate the factors predictive of low PbtO 2 . Nonlinear es timation examined variance in PbtO 2 . The t-tests were used to examine differences in the acute physiological parameters for ischemia (dichotomized at PbtO 2 < 20 mm Hg), the role of preexisting hypertension, and renal disease. Intergroup comparisons of the various clinical pathological entities, clinical syndromes, and treatment episodes were performed using t-tests and multivariate analysis of variance. The effect of nicardipine therapy on patients dichotomized as ischemic was performed using unpaired t-tests.
Results

Clinical and Demographic Data
All 30 patients with acute brain disease requiring intravenous nicardipine for treatment of hypertensive emergencies were prospectively evaluated, the majority of whom presented with TBI or aneurysmal SAH (80%). The ICP/PbtO 2 bolts were inserted in the right frontal lobe in 26 patients, whereas in 4 patients left-sided bolts were placed to avoid contused or "abnormal" CT-documented areas. The mean patient age was 55.1 ± 19.4 years, with a male/female ratio of 1:1.2. Preexisting hypertension was present in 40% of patients and renal abnormalities were detected in 10%. A history of seizures was reported in a single patient. Electrocardiographic abnormalities were recorded in 24% of patients. Sixty-three percent of patients presented in a coma. Craniotomy was performed in 50% of patients. Four patients (13.3%) died whereas good neurological outcome was documented in 66.7%, and 20% had persistent neurological disability (Table 1) .
Intravenous nicardipine was effective as a single firstline agent for the treatment of hypertension in 26 patients (87%) and in 54 (90%) of the hypertensive episodes. The mean duration of treatment was 2.85 ± 2.78 days (range 0.5 -12 days). In 4 patients (6 episodes), intravenous esmolol was used to suppress tachyarrhythmia (2 cases) and to control the patient's BP when maximal doses of nicardipine were ineffective (2 cases). Sixty episodes of acute hypertension were reported, with 63% of patients experiencing ≥ 1 hypertensive episode. Intravenous nicardipine was restarted and stopped according to clinical needs. A single patient with aneurysmal SAH receiving intravenous propofol experienced transient hypotension; nicardipine was withheld briefly and restarted later at a lower dose. Oral antihypertensive agents were used in 12 patients at hospital discharge. A single agent was required in 9 patients and multiple agents in 3 ( Table 1) . No relationship to preadmission hypertension was detected.
Optimization of PbtO 2 Prior to Nicardipine Infusion
Low PbtO 2 was detected in 50% of patients following initial resuscitation (TBI in 9 and aneurysmal SAH in 6). Although ICP had a negative correlation to PbtO 2 (r = −0.427, p = 0.04), multiple logistic regression analysis failed to show any effect of the acute physiological parameters on PbtO 2 following bolt placement. We found that ICP, CPP, and FiO 2 accounted for 7-11% of the variation in PbtO 2 (nonlinear estimation). A significant improvement in PbtO 2 was achieved over 11.06 ± 11.09 hours, using the PbtO 2 -directed critical care guide (p = 0.049, chi-square analysis). No significant differences were noted in the acute physiological parameters before and after cerebral resuscitation ( Table 2) .
Effects of Nicardipine on PbtO 2 , Physiological Parameters, and Ischemia
Prior to initiation of nicardipine, low PbtO 2 was documented in 36% of patients despite the PbtO 2 /critical care-guided protocol treatment. Treatment with intravenous nicardipine (first episode) resulted in a significant reduction in systolic BP, diastolic BP, and MABP with 4 hours of continuous infusion, an effect that was sustained at 8 hours (p < 0.0001, t-test) ( Fig. 1 upper) . None of the patients received blood transfusion during this period. No effect on ICP was observed. The PbtO 2 values remained unchanged despite a significant reduction in CPP (p < 0.001) (Fig. 1 lower; * ACE = angiotensin-converting enzyme; AVM = arteriovenous malformation; GCS = Glasgow Coma Scale; GOS = Glasgow Outcome Scale; IV = intravenous; IVH = intraventricular hemorrhage; SD = standard deviation.
those in the nonischemic group (p = 0.01) ( Table 4 ). Although at 4 hours 6 patients were still below the ischemic threshold, near doubling of mean PbtO 2 was observed (10.55 ± 6.69 vs 19.25 ± 13.14 mm Hg, p = 0.0021), despite the significant reduction in MABP and CPP (Fig.  2 upper) . Normobaric hyperoxia was still necessary at 8 hours (FiO 2 0.77 ± 0.279) to sustain adequate PbtO 2 in this group (R 2 = 0.316, p = 0.04) (Fig. 2 lower) .
Clinical Syndromes, Disease, and Other Variables
When the clinical syndromes were reviewed, pretreatment PbtO 2 was the highest in the acute posttraumatic hypertension group (34.76 ± 18.32 mm Hg) followed by posttraumatic hypertension (26.78 ± 9.10 mm Hg) and ACVS (20.59 ± 17.26 mm Hg) (p = 0.02). The presence of preexisting hypertension or renal disease had no effect on any of the acute physiological parameters including PbtO 2 . No significant difference among the SAH, TBI, or spontaneous ICH groups was recorded in the pretreatment PbtO 2 or any of the acute physiological parameters (t-test and multivariate analysis of variance). When all treatment episodes were collectively analyzed, reductions in systolic BP, diastolic BP, and MABP with 4 hours of continuous nicardipine infusion, an effect that was sustained at 8 hours (p < 0.0001, t-test) was recorded. No effect on ICP or PbtO 2 was noted, despite the lowered CPP during treatment (p < 0.001). Interestingly, the FiO 2 requirement was reduced at 8 hours compared with preinfusion (0.7 ± 0.293 vs 0.615 ± 0.290, p < 0.01) ( 
Discussion
The recent advances in multimodality neurocritical monitoring involving PbtO 2 and the emergence of critical care guidelines have facilitated the treatment of ischemia and the identification of pharmaceutical agents that may adversely affect tissue perfusion and oxygenation. 56 Several classes of antihypertensive agents are available for the treatment of acute hypertensive emergencies and their selection must be based on clinical indication. 10, 12, 59 An ideal antihypertensive agent should provide the following: immediate and controlled BP reduction of 15-20% to clinical effect within 30-60 minutes; reduction in MABP of 10-15% (rapid-acting and titratable intravenous therapy); and a safeguard against uncontrolled hypotension. Furthermore, in patients with acute brain disease there should be no reduction in cardiac output and CBF; maintenance of adequate CPP in patients with ischemic stroke and those with elevated ICP; controlled treatment of postoperative hypertension in previously normotensive patients; and no adverse effects on cerebral oxygenation. 48, 59 Although ICP/CPP protocols and even triple-H therapy have improved clinical outcomes, death due to SAH, TBI, and stroke remains unacceptably high. Over the past 10 years, since the introduction of brain tissue O 2 monitoring, attempts had been made to use normobaric hyperoxia, CPP elevation, induced hypertension, and optimization of hemoglobin to influence PbtO 2 . 57, 58 have reported that a PbtO 2 -directed clinical protocol is superior to using just ICP/ CPP following severe brain injury.
Clinical deterioration in neurologically impaired patients may be attributable to raised ICP and low CPP, cerebral edema, impaired cerebral autoregulation, cerebral vasospasm, ischemia and/or infarction, or from a combination of these factors. Furthermore, systemic factors such as BP, cardiac output, arterial O 2 content, and hemoglobin may reduce O 2 delivery to the brain resulting in anaerobic metabolism, lactic acidosis, excitatory neurotransmitter release, and neurotoxicity, thereby aggravating cerebral ischemia and resulting in cell death. 23 Although all patients were resuscitated using conventional means, 60% were found to have low PbtO 2 . This is not surprising because standard resuscitation protocols have been shown to be inadequate to prevent cerebral ischemia. 38, 58 In this study, prior to nicardipine infusion, the PbtO 2 / critical care-guided protocol optimized cerebral oxygenation within 26 hours with a relative risk reduction for ischemia of 78%. Normobaric hyperoxia was most influential in affecting PbtO 2 . Collectively, however, the various acute physiological parameters could only account for no more than 20% of the variation in PbtO 2 . The development of low cerebral oxygenation in 40% of our patients prior to drug treatment may be attributed to microvascular spasm and/or cerebral dysautoregulation related directly to the ictus. 27 The management of acute hypertension in acute cerebrovascular conditions is challenging, and consensus on optimal BP reductions or selection of pharmaceutical agent remains controversial. 9, 10, 22, 43, 48, 59 On the one hand, treatment of BP may decrease the risk for further hemorrhage in patients with ICH, minimize the risk for rupture of cerebral aneurysms, and, in the acute postoperative period, prevent reperfusion bleeds after resection of an arteriovenous malformation. On the other hand, in patients with low PbtO 2 , BP lowering may reduce CPP and thereby aggravate cerebral injury, particularly in the presence of elevated ICP. Although Broderick et al., 9 on behalf of the Stroke Council, recommended BP reduction to an MABP of < 130 mm Hg while maintaining a CPP level of > 70 mm Hg, whereas other investigators have recommended lower levels. 12, 39, 42, 43, 66 Blood pressure elevation in the acute postoperative period may lead to serious neurological and cardiovascular complications and may contribute to postoperative hematomas from sympathetic activation and increases in systemic vascular resistance. These require administration of intravenous antihypertensive agents that act rapidly and are easily titratable. 22 In the current study we treated a wide spectrum of general neurosurgical disorders, including ACVSs associated with hemorrhage (35.5%), postoperative hypertension (32.2%), and TBI (32.2%), all requiring intravenous BP control. Initial treatment with nicardipine resulted in a significant mean BP reduction of 20% within 4 hours, an effect that was sustained at 8 hours, with the mean systolic BP (140 mm Hg), diastolic BP (68 mm Hg), and MABP (92 mm Hg) well within our physiological parameters and as recommended by others without ICP elevation. 42, 43 The efficacy of nicardipine was ubiquitous in the various pathological entities and clinical syndromes, making it suitable for various neurosurgical conditions. Although some differences were seen in pretreatment PbtO 2 in the various clinical syndromes, it did not reach statistical significance to influence the effect of nicardipine on BP reduction or on PbtO 2 . Furthermore, it is easy to use as clinically required and is equally effective for multiple treatment episodes without adverse effect on cerebral oxygenation. As a single agent, however, nicardipine was not effective as the sole agent for the treatment of hypertensive emergencies in all patients. Although intravenous β-blockers have a distinct disadvantage in neurological disorders, because they reduce cardiac output and can adversely affect CBF, the onset of tachyarrhythmia necessitated its use in 4 patients. 48 Nicardipine is becoming a preferred agent over nitroprusside for the management of hypertensive emergencies. 40, 48, 67 It inhibits transmembrane influx of Ca ions into cardiac and smooth muscle without changing serum Ca concentration and is metabolized in the liver, with a favorable safety profile. 66 In contrast to β blockers, nicardipine selectively decreases BP via arterial dilation, which reduces systemic vascular resistance, but has no effect on ventricular preload, cardiac output, or left ventricular systolic performance and is particularly advantageous over other Ca channel blockers (diltiazem and verapamil), which are associated with cardiac suppression. 11, 54 In addition, nicardipine has no venodilatory effects. This is particularly useful in preventing hypotensive episodes, providing stricter BP control, facilitating ease of titration, and not producing any ICP elevations. 6 In an open-labeled randomized trial comparing the combinations of nicardipine/enalaprilat and enalaprilat/labetalol for the treatment of postcraniotomy hypertension, both groups were shown to effectively control systolic BP. 31 Although α-β blockers are also popular, their effects on cardiac output are marginal. Qureshi et al. 43 have shown effective BP control within 24 hours when using labetalol (α-β blocker) as a first-line agent, augmented by nitroprusside or hydralazine, in patients with intra cerebral hematomas. The effect of nitroprusside on BP is quite labile, requiring frequent dose adjustments to prevent hypotension, and the risk of toxicity is ever present during prolonged infusion. The use of this agent should therefore be avoided in patients with neurological conditions. 39, 42, 48 Clonidine has sedative effects whereas nicardipine has pos itive effects on electroencephalography.
14 Moreover, these agents have not been evaluated in relation to their ef fect on brain oxygenation.
The reduction in BP was achieved while maintaining CPP at > 70 mm Hg (mean 79 mm Hg in this study). Reinert et al. 44 have shown that CPP elevations beyond 78 mm Hg have no significant effect on PbtO 2 , whereas Robertson et al. 47 have cautioned that complications may increase simply because ICP/CPP protocols have been used. The 20% reduction in CPP had no deleterious effect on PbtO 2 levels, and this is probably due to the arterial dilatory properties of nicardipine, thereby improving CBF. The specific arterial dilatory properties of intravenous nicardipine have been studied in neurological diseases. Intravenous nicardipine has significant vasodilatory ef- fects on both small and large vessels of the brain, whereas intraarterial nicardipine has an immediate and sustained effect on cerebral vasospasm. In addition, locally applied nicardipine in prolonged-release implants has reduced the incidence of delayed ischemic deficits. 6, 28, 29 The neuroprotective effects of nicardipine may extend beyond its well-described role as an antihypertensive and antivasospastic agent. It reverses endothelin-1-related vasospasm in experimental SAH and counteracts the microanatomical changes in spontaneously hypertensive rats. 4, 5 In 1985, Gaab et al. 20 demonstrated that nicardipine dilates cerebral blood vessels and increases cerebral O 2 tension, whereas Rosenbaum et al. 49, 50 reported that patients treated with intravenous nicardipine therapy within 6 hours had more favorable outcomes than did those beginning therapy after 6 hours and that hyperbaric O 2 and nicardipine accelerated neurological recovery after 15 min utes of complete global ischemia. 36, 45 Furthermore, ni cardipine has been reported to decrease aneurysmal vasospasm. 8, 28 Additionally, in patients with small-to medium-sized acute intracerebral bleeds, autoregulation of CBF (determined by PET scanning) was preserved with MABP reductions using nicardipine. 41 Although our study findings may be weakened by the size of the cohort, the absence of a comparison with other standard antihypertensive agents on PbtO 2 response, the presence of heterogeneous disease, and regional PbtO 2 readings, the present study is, to our knowledge, the first to evaluate the effects of nicardipine on cerebral oxygenation in the setting of acute brain pathological entities.
In patients with low PbtO 2 , treatment with nicardipine resulted in an 87% mean improvement in PbtO 2 , with a relative risk reduction for ischemia of 31%, despite 18% reduction in MABP and 19% reduction in CPP. Because the acute physiological parameters accounted for no more than 20% of the variation in PbtO 2 and no blood transfusion was necessary, nicardipine therapy itself probably resulted in significant improvement in regional O 2 delivery even though there was a continued need for normobaric hyperoxia, suggesting that not all the microvascular spasm could be reversible with nicardipine. 59 The Hagen-Poiseuille law, which represents flow of . Regional brain tissue O 2 , which measures the partial pressure of oxygen, has shown a moderate correlation to FiO 2 and CPP. Therefore, a minor increase in radius can have a major impact on the enhancement of CBF because of the exponential effect of the increase in vessel radius and could explain the beneficial effects of nicardipine in situations of low cerebral oxygenation. 13, 18, 20, 25, 52 The current study findings suggests that intravenous nicardipine is a safe and effective arterial dilator that has beneficial effect on CBF in acute brain disease, thereby improving O 2 delivery.
Conclusions
Intravenous nicardipine is safe and effective as a firstline agent for the treatment of hypertensive emergencies associated with acute brain disease such as aneurysmal SAH, ICH, TBI, as well as in postoperative neurosurgically treated patients. Repeated episodic treatment of BP to physiological levels resulted in reduction of CPP without deleterious effect on PbtO 2 . In patients with low cerebral oxygenation, nicardipine improved PbtO 2 most probably via dilation of the cerebral arteries and arterioles. Therefore, together with a PbtO 2 -directed protocol, nicardipine resulted in improvement of CBF and O 2 delivery with the potential to reduce cerebral ischemia.
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TABLE 4
Comparison of the effects of intravenous nicardipine on systemic and neurological parameters for all 60 
